Matilda Juusola1, Anna Parkkola1, Taina Härkönen1, Heli Siljander1, Jorma Ilonen2, Hans K Åkerblom1, Mikael Knip3. 1. Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland. 2. Immunogenetics Laboratory, University of Turku, Turku, Finland Department of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland. 3. Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland Folkhälsan Research Center, University of Helsinki, Helsinki, Finland Tampere Center for Child Health Research, Tampere University Hospital, Tampere, Finland mikael.knip@helsinki.fi.
Abstract
OBJECTIVE: This study assessed the relationship between autoantibodies against zinc transporter 8 (ZnT8A) and disease characteristics at diagnosis of type 1 diabetes and during the first 2 years. RESEARCH DESIGN AND METHODS: Children, younger than 15 years of age (n = 723) who were newly diagnosed with diabetes, were analyzed for ZnT8A, other diabetes-associated autoantibodies, HLA DR-DQ alleles, and metabolic status, which was monitored by pH, plasma glucose, and occurrence of ketoacidosis at diagnosis and through follow-up of C-peptide concentrations, exogenous insulin dose, and glycosylated hemoglobin for 2 years after the diagnosis. RESULTS: ZnT8A positivity was detected in 530 children (73%). Positivity for ZnT8A was associated with older age (median 8.9 vs. 8.2 years, P = 0.002) and more frequent ketoacidosis (24% vs. 15%, P = 0.013). Children carrying the HLA DR3 allele were less often ZnT8A positive (66% vs. 77%, P = 0.002) than others. ZnT8A-positive children had lower serum C-peptide concentrations (P = 0.008) and higher insulin doses (P = 0.012) over time than their ZnT8A-negative peers. CONCLUSIONS: Positivity for ZnT8A at diagnosis seems to reflect a more aggressive disease process before and after diagnosis.
OBJECTIVE: This study assessed the relationship between autoantibodies against zinc transporter 8 (ZnT8A) and disease characteristics at diagnosis of type 1 diabetes and during the first 2 years. RESEARCH DESIGN AND METHODS: Children, younger than 15 years of age (n = 723) who were newly diagnosed with diabetes, were analyzed for ZnT8A, other diabetes-associated autoantibodies, HLA DR-DQ alleles, and metabolic status, which was monitored by pH, plasma glucose, and occurrence of ketoacidosis at diagnosis and through follow-up of C-peptide concentrations, exogenous insulin dose, and glycosylated hemoglobin for 2 years after the diagnosis. RESULTS:ZnT8A positivity was detected in 530 children (73%). Positivity for ZnT8A was associated with older age (median 8.9 vs. 8.2 years, P = 0.002) and more frequent ketoacidosis (24% vs. 15%, P = 0.013). Children carrying the HLA DR3 allele were less often ZnT8A positive (66% vs. 77%, P = 0.002) than others. ZnT8A-positive children had lower serum C-peptide concentrations (P = 0.008) and higher insulin doses (P = 0.012) over time than their ZnT8A-negative peers. CONCLUSIONS: Positivity for ZnT8A at diagnosis seems to reflect a more aggressive disease process before and after diagnosis.
Authors: M Kukko; T Kimpimäki; S Korhonen; A Kupila; S Simell; R Veijola; T Simell; J Ilonen; O Simell; M Knip Journal: J Clin Endocrinol Metab Date: 2005-02-15 Impact factor: 5.958
Authors: J Tuomilehto; R Lounamaa; E Tuomilehto-Wolf; A Reunanen; E Virtala; E A Kaprio; H K Akerblom Journal: Diabetologia Date: 1992-01 Impact factor: 10.122
Authors: Janet M Wenzlau; Kirstine Juhl; Liping Yu; Ong Moua; Suparna A Sarkar; Peter Gottlieb; Marian Rewers; George S Eisenbarth; Jan Jensen; Howard W Davidson; John C Hutton Journal: Proc Natl Acad Sci U S A Date: 2007-10-17 Impact factor: 11.205
Authors: Anette G Ziegler; Marian Rewers; Olli Simell; Tuula Simell; Johanna Lempainen; Andrea Steck; Christiane Winkler; Jorma Ilonen; Riitta Veijola; Mikael Knip; Ezio Bonifacio; George S Eisenbarth Journal: JAMA Date: 2013-06-19 Impact factor: 56.272
Authors: Janet M Wenzlau; Yu Liu; Liping Yu; Ong Moua; Kimberly T Fowler; Sampathkumar Rangasamy; Jay Walters; George S Eisenbarth; Howard W Davidson; John C Hutton Journal: Diabetes Date: 2008-06-30 Impact factor: 9.461
Authors: MacKenzie D Williams; Rhonda Bacher; Daniel J Perry; C Ramsey Grace; Kieran M McGrail; Amanda L Posgai; Andrew Muir; Srikar Chamala; Michael J Haller; Desmond A Schatz; Todd M Brusko; Mark A Atkinson; Clive H Wasserfall Journal: Diabetes Date: 2021-01-08 Impact factor: 9.461
Authors: Petra M Pöllänen; Samppa J Ryhänen; Jorma Toppari; Jorma Ilonen; Paula Vähäsalo; Riitta Veijola; Heli Siljander; Mikael Knip Journal: J Clin Endocrinol Metab Date: 2020-12-01 Impact factor: 5.958